Surprisingly, the protein level of p53 and its target p21 did not differ between MAPKi-sensitive and -resistant melanoma cell lines neither on a basal level nor after cisplatin treatment (Fig. 2b, Suppl. This evidence concerns the gene TP53 and melanoma.